Lantheus Holdings Inc
NASDAQ:LNTH
Intrinsic Value
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. [ Read More ]
The intrinsic value of one LNTH stock under the Base Case scenario is 134.91 USD. Compared to the current market price of 63.81 USD, Lantheus Holdings Inc is Undervalued by 53%.
Valuation Backtest
Lantheus Holdings Inc
Run backtest to discover the historical profit from buying and selling LNTH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lantheus Holdings Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 713.7m |
Receivables | 284.3m |
Other Current Assets | 87.9m |
Non-Current Assets | 565.3m |
PP&E | 192m |
Intangibles | 213.2m |
Other Non-Current Assets | 160.1m |
Current Liabilities | 187.4m |
Accounts Payable | 41.2m |
Accrued Liabilities | 132.1m |
Other Current Liabilities | 14.1m |
Non-Current Liabilities | 647.9m |
Long-Term Debt | 561.7m |
Other Non-Current Liabilities | 86.2m |
Earnings Waterfall
Lantheus Holdings Inc
Revenue
|
1.3B
USD
|
Cost of Revenue
|
-586.9m
USD
|
Gross Profit
|
709.5m
USD
|
Operating Expenses
|
-335.4m
USD
|
Operating Income
|
374.1m
USD
|
Other Expenses
|
-47.5m
USD
|
Net Income
|
326.7m
USD
|
Free Cash Flow Analysis
Lantheus Holdings Inc
What is Free Cash Flow?
LNTH Profitability Score
Profitability Due Diligence
Lantheus Holdings Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Lantheus Holdings Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
LNTH Solvency Score
Solvency Due Diligence
Lantheus Holdings Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
Lantheus Holdings Inc's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LNTH Price Targets Summary
Lantheus Holdings Inc
According to Wall Street analysts, the average 1-year price target for LNTH is 99.04 USD with a low forecast of 82.82 USD and a high forecast of 134.4 USD.
Ownership
LNTH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LNTH Price
Lantheus Holdings Inc
Average Annual Return | 34.22% |
Standard Deviation of Annual Returns | 69.44% |
Max Drawdown | -69% |
Market Capitalization | 4.4B USD |
Shares Outstanding | 68 551 400 |
Percentage of Shares Shorted | 9.13% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 612 full-time employees. The company went IPO on 2015-06-25. The firm classify its commercial products in three categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other revenue. Its products in its precision diagnostics category includes DEFINITY, TechneLite, NEUROLITE, Xenon-133, Cardiolite, Gallium-67 and Thallium-201. Its products in its radiopharmaceutical oncology category includes PYLARIFY and AZEDRA. Its products in its strategic partnerships and other revenue product category includes RELISTOR, Automated Bone Scan Index (aBSI) and PYLARIFY AI. In addition to its commercial products and strategic partnerships with third parties, it also has ongoing clinical development programs, such as 1095 and LMI 1195. Its products are sold in both the United States and internationally.
Contact
IPO
Employees
Officers
The intrinsic value of one LNTH stock under the Base Case scenario is 134.91 USD.
Compared to the current market price of 63.81 USD, Lantheus Holdings Inc is Undervalued by 53%.